TB-500 is a synthetic peptide corresponding to the actin-binding fragment of thymosin beta-4, a naturally occurring regulatory protein. It is marketed within research and wellness settings for tissue-repair and recovery contexts, though published human clinical evidence for the fragment itself is limited. It is not an FDA-approved drug.
TB-500 ranks as the #11 most-prescribed compounded product on ScriptLinkRx, based on cumulative order volume across clinics ordering through the platform as of mid-2026. Provider interest in TB-500 tracks closely with the broader "recovery peptide" category, and its regulatory posture in 2026 mirrors that of BPC-157: a substance recently moved off FDA's Category 2 list and now awaiting formal advisory-committee review. This page summarizes what TB-500 is, how clinics encounter it, and the compliance considerations providers should weigh before sourcing it — without asserting outcomes that the current evidence base does not support.
What TB-500 Is
TB-500 is a laboratory-synthesized peptide whose sequence corresponds to the central actin-binding region of thymosin beta-4 (Tβ4), an endogenous, 43-amino-acid protein found in most human tissues. The peptide most often sold under the "TB-500" label is a short fragment (commonly the LKKTETQ actin-binding motif and adjacent residues) rather than the full-length Tβ4 molecule.
Thymosin beta-4 itself participates in actin sequestration, cell migration, and cytoskeletal regulation, and the full-length protein has been studied in various preclinical and early clinical wound-healing and ophthalmic contexts. An important distinction for providers: much of the frequently cited biological rationale derives from research on full-length Tβ4, not on the shorter TB-500 fragment. The two are related but are not interchangeable, and the fragment lacks certain functional domains present in the parent protein. TB-500 is best understood as a research peptide with a mechanistic hypothesis rather than a characterized therapeutic agent.
Because TB-500 is not FDA-approved and has not completed the review process that would establish an approved indication, any description of its role in patient care is necessarily framed in terms of how some clinics use it, not what it has been shown to do.
How Providers Use It in Practice
TB-500 appears most often in the practice contexts that also drive interest in other recovery-oriented peptides: sports-medicine and regenerative practices, some longevity and wellness clinics, and integrative or functional-medicine settings. In these environments, some providers order TB-500 in the context of soft-tissue recovery, musculoskeletal, or general-recovery protocols, frequently alongside or as an alternative to BPC-157.
It is worth stating plainly that this usage rests on a thin human evidence base. As of mid-2026, there are no completed, published randomized human trials of the TB-500 fragment for musculoskeletal or tissue-repair indications; the human data that exist largely concern the full-length parent protein. Providers evaluating TB-500 are therefore operating in an area where marketing claims commonly outrun the peer-reviewed literature. A regulatory-literate clinician should treat any promotional statement about healing, regeneration, or performance as unverified with respect to this specific fragment.
Prescribing decisions involving TB-500 are the responsibility of the licensed provider, who must independently assess the clinical rationale, informed-consent obligations, and the substance's regulatory status for each individual patient. Nothing here should be read as a recommendation to use TB-500 for any purpose.
Forms and Combinations Available Through Compounding
When TB-500 is compounded, it is typically prepared by 503A compounding pharmacies as a lyophilized (freeze-dried) powder for reconstitution, intended for subcutaneous administration once reconstituted. Because it is a sterile injectable preparation, sterility and quality controls are central rather than incidental considerations.
Compounding pharmacies sometimes prepare TB-500 as a single agent and sometimes in combination formulations — most commonly paired with BPC-157 in a single recovery-oriented preparation. As with any combination product, the individualized clinical justification for combining agents rests with the prescriber; a blended product does not carry any independent regulatory standing, and each component must independently satisfy the applicable compounding requirements.
The general rationale for compounding, rather than dispensing a manufactured product, is patient-specific customization: there is no FDA-approved TB-500 drug product to prescribe, so any clinical use necessarily flows through a compounding pharmacy operating under the relevant statutory framework. That absence of an approved reference product is itself a defining feature of this compound's regulatory profile, discussed below. This page does not provide strengths, concentrations, reconstitution instructions, or dosing schedules; those are clinical decisions outside its scope.
Regulatory Status and Provider Considerations
TB-500 is not FDA-approved for any indication, and no manufactured thymosin beta-4 or TB-500 drug product is currently approved and marketed in the United States as of July 2026. Its status under the compounding framework has shifted meaningfully in 2026 and warrants careful attention.
- Category 2 history. TB-500 (as a thymosin beta-4 fragment) was among the peptide bulk drug substances placed in Category 2 of FDA's interim 503A bulk drug substances list — the category for substances FDA identified as potentially presenting significant safety risks for use in compounding.
- April 2026 removal. In April 2026, FDA removed a group of peptides, including TB-500, from Category 2 of the interim 503A list, with the reclassification taking effect in late April 2026.
- PCAC review scheduled July 2026. FDA announced a Pharmacy Compounding Advisory Committee (PCAC) meeting for July 23–24, 2026, at which the committee is to consider TB-500 and several other peptides (including BPC-157) for potential inclusion on the Section 503A bulk drug substances list.
The critical interpretive point for providers: removal from Category 2 does not mean TB-500 has been cleared, approved, or affirmatively authorized for compounding. It means the substance has been moved out of the "significant safety risks" bucket and into a pending evaluation. Until PCAC completes its review and FDA acts on that recommendation, TB-500 remains a substance without approved status on the 503A list, and the outcome of the July 2026 review is not predetermined. Providers should verify the then-current listing status directly with FDA and confirm how their sourcing pharmacy is handling the substance, rather than relying on the April 2026 reclassification as a green light.
Providers should also recognize that TB-500 has no USP monograph and no approved reference drug, both of which factor into a compounding pharmacy's legal basis for using it. Because the regulatory landscape here is actively changing, every statement in this section is date-stamped to July 2026 and should be re-verified before it informs a clinical or sourcing decision.
Sourcing and Quality: What to Ask a Compounding Pharmacy
Given the sterile-injectable nature of TB-500 and its unsettled regulatory footing, diligence on the compounding pharmacy is essential. Providers evaluating a source may wish to confirm:
- API source and Certificate of Analysis (CoA). Where does the pharmacy obtain the peptide active ingredient, and can it provide a lot-specific CoA documenting identity and purity from a qualified supplier?
- Regulatory basis for compounding the substance. How does the pharmacy justify compounding TB-500 in light of its current 503A listing status, the absence of a USP monograph, and the absence of an approved reference product?
- USP compliance. Does the pharmacy operate under USP <795> (non-sterile), <797> (sterile preparations), and <800> (hazardous drugs) as applicable? Sterile injectables implicate <797> directly.
- Potency and sterility testing. Are finished preparations tested for potency, sterility, and endotoxin, and are results available? Endotoxin and sterility failures are a documented concern for compounded sterile peptide products generally.
- Beyond-use dating. How is the beyond-use date (BUD) for the reconstituted and unreconstituted product established and supported?
- State licensure and inspection history. Is the pharmacy licensed in the provider's state, and what is its inspection and disciplinary record?
Clinics order compounded medications through platforms like ScriptLinkRx, which connect licensed providers with licensed compounding pharmacies; regardless of the ordering channel, the questions above remain the provider's responsibility to resolve.
Frequently Asked Questions
Is TB-500 FDA-approved?
No. TB-500 is not an FDA-approved drug, and there is no approved thymosin beta-4 or TB-500 finished drug product marketed in the United States as of July 2026. Any clinical use flows through compounding, and its status on FDA's 503A bulk substances list remains under review.
Does the April 2026 removal from Category 2 mean TB-500 is now approved for compounding?
No. Removal from Category 2 means FDA moved TB-500 out of the "significant safety risks" category, not that it has been affirmatively cleared. The substance was scheduled for PCAC review on July 23–24, 2026, and its listing status should be verified directly with FDA before being relied upon.
How is TB-500 different from full-length thymosin beta-4?
TB-500 is a short synthetic fragment corresponding to the actin-binding region of thymosin beta-4, whereas the parent protein is a full 43-amino-acid molecule with additional functional domains. Much of the cited biological research concerns the full-length protein rather than the fragment, so the two should not be treated as equivalent.
What does the human evidence show for TB-500?
Human clinical evidence for the TB-500 fragment specifically is limited; as of mid-2026 there are no completed, published randomized human trials for musculoskeletal or tissue-repair use. Providers should regard promotional recovery or healing claims about the fragment as unverified in humans.
How is TB-500 typically supplied when compounded?
It is most often prepared as a lyophilized powder for reconstitution and subcutaneous use, sometimes as a single agent and sometimes combined with BPC-157. Because it is a sterile injectable, sterility, potency, and endotoxin testing are central sourcing considerations.
Related Reading
- See where TB-500 ranks among the most-prescribed compounded medications
- BPC-157: Provider Overview and Regulatory Status
- GHK-Cu (Copper Peptide): Provider Overview
Sources
- FDA, "Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks" — https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
- FDA, "Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act" — https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act
- FDA, Pharmacy Compounding Advisory Committee (PCAC) — meeting materials and Federal Register notice for the July 23–24, 2026 meeting — https://www.fda.gov/advisory-committees/human-drug-advisory-committees/pharmacy-compounding-advisory-committee
